These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28386699)

  • 41. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
    Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD
    Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music.
    Barrett FS; Preller KH; Herdener M; Janata P; Vollenweider FX
    Cereb Cortex; 2018 Nov; 28(11):3939-3950. PubMed ID: 29028939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of 5-HT
    Wang X; Cao N; Ni J; Si J; Gu B; Karl-Erik A
    Neurosci Lett; 2018 Nov; 687():196-201. PubMed ID: 30278246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
    Kometer M; Schmidt A; Jäncke L; Vollenweider FX
    J Neurosci; 2013 Jun; 33(25):10544-51. PubMed ID: 23785166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors.
    Egan CT; Herrick-Davis K; Miller K; Glennon RA; Teitler M
    Psychopharmacology (Berl); 1998 Apr; 136(4):409-14. PubMed ID: 9600588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antagonism of the LSD cue by putative serotonin antagonists: relationship to inhibition of in vivo [3H]spiroperidol binding.
    Nielsen EB; Ginn SR; Cunningham KA; Appel JB
    Behav Brain Res; 1985 Aug; 16(2-3):171-6. PubMed ID: 2931089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
    Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
    Ferry RC; Unsworth CD; Molinoff PB
    Mol Pharmacol; 1993 May; 43(5):726-33. PubMed ID: 8388988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
    Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
    J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of the 5-HT
    Holze F; Avedisian I; Varghese N; Eckert A; Liechti ME
    Front Pharmacol; 2021; 12():711255. PubMed ID: 34326773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression.
    Delli Pizzi S; Chiacchiaretta P; Sestieri C; Ferretti A; Onofrj M; Della Penna S; Roseman L; Timmermann C; Nutt DJ; Carhart-Harris RL; Sensi SL
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2023 Jul; 8(7):768-776. PubMed ID: 37003409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
    Blair JB; Marona-Lewicka D; Kanthasamy A; Lucaites VL; Nelson DL; Nichols DE
    J Med Chem; 1999 Mar; 42(6):1106-11. PubMed ID: 10090793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Homology modeling of the human 5-HT1A, 5-HT 2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation.
    Yap BK; Buckle MJ; Doughty SW
    J Mol Model; 2012 Aug; 18(8):3639-55. PubMed ID: 22354276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats.
    Fantegrossi WE; Harrington AW; Eckler JR; Arshad S; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
    Psychopharmacology (Berl); 2005 Sep; 181(3):496-503. PubMed ID: 15983786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
    J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5-Hydroxytryptamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide.
    Gresch PJ; Barrett RJ; Sanders-Bush E; Smith RL
    J Pharmacol Exp Ther; 2007 Feb; 320(2):662-9. PubMed ID: 17077317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation.
    Wang CD; Gallaher TK; Shih JC
    Mol Pharmacol; 1993 Jun; 43(6):931-40. PubMed ID: 8316224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
    Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.